Novavax addresses urgent global public health needs with innovative technology
Recombinant Nanoparticle Vaccine Technology
Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring immunity or traditional vaccines. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.
How we create our nanoparticles
- Select genetic sequences to encode vaccine antigens
- Genes are cloned into baculovirus (BV)
- BV infects Sf9 insect cells
- Antigens are expressed and purified as multimeric nanoparticles
- Immunogenic particle with antigens in native configuration are created
Novavax’ recombinant protein nanoparticle vaccine technology
Matrix-M™ adjuvant technology stimulates strong responses
Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing.
Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.
- Induces the influx of antigen-presenting cells (APC), which enhance activated T cell, B cell, and APC populations.
- Increases neutralizing antibodies and induces long-lasting memory B cells, which enhance B-cell immunity and recruit and increase the frequency of CD4+ and CD8+ T cells that enhance T-cell immunity.
- Matrix-M provides strong and long-lasting immune responses, which can enable dose-sparing.